Back to the leaderboard
@a_a_free · Long APGE
Read asLong APGE+2 more
Since the call—
unrankedThe analyst's rank today
High · 0.94Confidence
Sun, Oct 18Tweeted
Mon, Oct 19 closeCounted from
not in the basket todayBasket
Rank per close
—Oct 19
A.A@a_a_freeThis is what one of the best BD in IBD and immunology. That's why $SYRE and $ORKA are expensive and probably at least one of them will be taken by 2027 if not both. When you see the number of companies who recently went IPO, private companies and the recent deals to start
Bioinvestor24@bioinvestor24$ABBV CEO and mgt just confirmed their focus in IBD and immunology on combinations and extended half life and as being the next frontier $SYRE CEO affirms his assets are in a different tier vs Abbv .. co formulation volumes , extended half life and exposure.
